Age-Related Macular DegenerationCORE-GANCT07556406
Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
An observational study of Age-Related Macular Degeneration and Geographic Atrophy, run by University of California, San Francisco at 1 site in United States.
Trial summary
This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Age-Related Macular Degeneration, Geographic Atrophy
- What is being tested?
- Optical coherence tomography and Microperimetry
- How many people
- 80 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Jun 2025to 11 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with age-related macular degeneration.
Who may be able to join
- Subjects must be 55+ years of age Subjects in the "Intermediate AMD Observation Arm" must have intermediate age-related macular degeneration in one eye
- Subjects in the "GA Observation Arm", "GA Continuing Treatment Arm", and "GA Treatment Arm" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.
Who cannot join
- Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point.
- Subjects with a baseline size of GA > 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).
- Subjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g/dL) on 5 or more days in the past month.
- Evidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):
- Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy
- Branch or central retinal vein or artery occlusion
Show all 11Show fewer
- Macular hole
- Pathologic myopia
- Uveitis
- Pseudovitelliform maculopathy
- Intraoperative surgery within the last 90 days prior to study eye enrollment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of California, San Francisco
San Francisco, California, 94143
Jay M Stewart, MD, 628-206-3123, eyestudy@ucsf.edu
Jay M Stewart, MD
About this study
This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.
- Being tested
- Optical coherence tomography, Microperimetry
- Keywords
- age-related macular degeneration, geographic atrophy
- Medical subject headings
- Macular Degeneration, Geographic Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Optical coherence tomographyDiagnostic test
Also called OCT
High-resolution imaging method used to evaluate the structure of the retina
MicroperimetryDiagnostic test
A functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision.
| Study group | Role | What they receive |
|---|---|---|
| Non-central geographic atrophy not being treated | Patients with age-related macular degeneration who have geographic atrophy that does not involve the fovea. Receives: Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry | |
| Intermediate age-related macular degeneration | Patients with intermediate age-related macular degeneration Receives: Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry | |
| Non-central geographic atrophy currently being treated | Patients with non-central geographic atrophy from age-related macular degeneration who are currently receiving treatment for this condition. Receives: Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry | |
| Non-central geographic atrophy initiating treatment | Patients with non-central geographic atrophy from age-related macular degeneration who will be starting to receive treatment for this condition. Receives: Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry |
What is being measured
The primary outcome is the main question the study is designed to answer.
Geographic atrophy progression rate
Quantify the progression rate of geographic atrophy toward the foveal center over time
Measured: 1 year
Secondary outcomes (1)
Longitudinal progression of macular sensitivity over time
Measure macular sensitivity over time.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start11 Jun 2025
- Primary completion11 Jun 2027 (estimated)
- Study completion11 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age-Related Macular DegenerationStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jay Stewart, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07556406
- Sponsor's protocol ID
- 25-43635
- Acronym
- CORE-GA
- Status last verified
- Apr 2026
- First submitted
- 22 Apr 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
- ClinicalTrials.gov ID
- NCT07556406
- Acronym / sponsor ID
- CORE-GA / 25-43635
- Keywords
- age-related macular degeneration, geographic atrophy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 11 Jun 2025 (actual)
- Primary completion
- 11 Jun 2027 (estimated)
- Study completion
- 11 Jun 2027 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Non-central geographic atrophy not being treated | – | Diagnostic Test: Optical coherence tomography, Diagnostic Test: MicroperimetryPatients with age-related macular degeneration who have geographic atrophy that does not involve the fovea. |
| Intermediate age-related macular degeneration | – | Diagnostic Test: Optical coherence tomography, Diagnostic Test: MicroperimetryPatients with intermediate age-related macular degeneration |
| Non-central geographic atrophy currently being treated | – | Diagnostic Test: Optical coherence tomography, Diagnostic Test: MicroperimetryPatients with non-central geographic atrophy from age-related macular degeneration who are currently receiving treatment for this condition. |
| Non-central geographic atrophy initiating treatment | – | Diagnostic Test: Optical coherence tomography, Diagnostic Test: MicroperimetryPatients with non-central geographic atrophy from age-related macular degeneration who will be starting to receive treatment for this condition. |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with age-related macular degeneration.
Key inclusion criteria (2 listed)
- Subjects must be 55+ years of age Subjects in the "Intermediate AMD Observation Arm" must have intermediate age-related macular degeneration in one eye
- Subjects in the "GA Observation Arm", "GA Continuing Treatment Arm", and "GA Treatment Arm" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.
Key exclusion criteria (11 listed)
- Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point.
- Subjects with a baseline size of GA > 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).
- Subjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g/dL) on 5 or more days in the past month.
- Evidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):
- Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Optical coherence tomographyAlso: OCTHigh-resolution imaging method used to evaluate the structure of the retina | Diagnostic test | Intermediate age-related macular degeneration, Non-central geographic atrophy currently being treated, Non-central geographic atrophy initiating treatment, Non-central geographic atrophy not being treated |
| MicroperimetryA functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision. | Diagnostic test | Intermediate age-related macular degeneration, Non-central geographic atrophy currently being treated, Non-central geographic atrophy initiating treatment, Non-central geographic atrophy not being treated |
Primary outcome
Geographic atrophy progression rate
Time frame: 1 year
Quantify the progression rate of geographic atrophy toward the foveal center over time
1 secondary outcome
Longitudinal progression of macular sensitivity over time
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Age-Related Macular Degeneration
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
RecruitingObservational study
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Age-related Macular Degeneration (AMD)
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingObservational study
Retinal Pigment Epithelium Safety Study For Patients In B4711001
Age Related Macular Degeneration
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jay Stewart, MD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Age-Related Macular Degeneration and Geographic Atrophy, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jay M Stewart, MD ((628) 206-3123, eyestudy@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Geographic atrophy progression rate (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.